<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694577</url>
  </required_header>
  <id_info>
    <org_study_id>03-179</org_study_id>
    <nct_id>NCT00694577</nct_id>
  </id_info>
  <brief_title>Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer</brief_title>
  <official_title>Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer: A Phase I Feasibility/Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility of partial breast irradiation in&#xD;
      participants with early invasive or non-invasive breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  In this study, radiotherapy is given only to a portion of the breast around the tumor&#xD;
           bed using external radiation treatments. This approach is called &quot;partial breast&#xD;
           irradiation&quot;.&#xD;
&#xD;
        -  Participants will undergo a planning session for the radiation treatments. This planning&#xD;
           will be done by CT scan days or weeks before the start of treatment. This planning&#xD;
           process is the same as that used to plan conventional radiation therapy treatments.&#xD;
&#xD;
        -  Radiation therapy will begin 4-12 weeks after the last surgery of the breast in&#xD;
           individuals not receiving chemotherapy first. For individuals receiving chemotherapy&#xD;
           before radiation therapy, radiation therapy will start 2-6 weeks after ending&#xD;
           chemotherapy.&#xD;
&#xD;
        -  We will be studying three levels of radiation doses to see which is best. The dose the&#xD;
           participant receives will depend upon when they are enrolled on the trial.&#xD;
&#xD;
        -  Participants will receive radiation treatment twice each day for 4 or 5 treatment days,&#xD;
           with an overall treatment time of one week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the feasibility of PBI directed XRT in selected stages 0 and 1 female breast cancer patients within each dose level.</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the rate and severity of cutaneous toxicity</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the risk of breast fibrosis and fat necrosis</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate cosmetic outcome</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate patient satisfaction</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate local and distant control rates</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Ductal Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Participants 1-100 Partial Breast Irradiation using 32 Gy / 8 fractions BID in one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Participants 101-200 Partial Breast Irradiation using 36 Gy / 9 fractions BID in one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Participants 201-330 Partial Breast Irradiation using 40 Gy / 10 fractions BID in one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Partial Breast Irradiation using 32 Gy / 8 fractions</intervention_name>
    <description>32 Gy-8 Treatments, 4 Treatment Days</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>PBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Partial Breast Irradiation using 36 Gy / 9 fractions</intervention_name>
    <description>36 Gy- 9 Treatments, 4 1/2 Treatment Days</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>PBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Partial Breast Irradiation using 40 Gy /10 fractions</intervention_name>
    <description>40 Gy-10 Treatments, 5 Treatment days</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>PBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed unicentric Stage I Invasive Ductal breast cancer.&#xD;
             Histologically negative tumor margin 2mm or more from any inked edges, or no tumor in&#xD;
             re-excision specimen or final shaved specimen.&#xD;
&#xD;
          -  Patient may have been treated with adjuvant chemotherapy, or be on adjuvant hormonal&#xD;
             therapy or begin hormonal therapy following XRT&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  ECOG Performance Status 0&#xD;
&#xD;
          -  Required laboratory data as outlined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multicentric IDC of the breast defined as discontiguous tumors separated by at least&#xD;
             5cm of uninvolved tissue&#xD;
&#xD;
          -  Multifocal IDC of the breast, defined as discontiguous discrete foci of invasive&#xD;
             carcinoma, separated by uninvolved intervening tissue, but within an overall span of&#xD;
             5cm, or within the same breast quadrant or subareolar central region&#xD;
&#xD;
          -  Tumor &gt; 2.0cm, nodal involvement, or metastatic involvement&#xD;
&#xD;
          -  Histological evidence of: lymphovascular invasion; blood vessel invasion; extensive&#xD;
             intraductal component; invasive lobular carcinoma and infiltrating carcinoma of mixed&#xD;
             ductal and lobular type; DCIS with microinvasion and DCIS suspicious for&#xD;
             microinvasion; infiltrating micropapillary carcinoma&#xD;
&#xD;
          -  Known mutation carrier, including BRCA1 and BRCA2&#xD;
&#xD;
          -  History of cosmetic or reconstructive breast surgery&#xD;
&#xD;
          -  Psychiatric illness which would prevent the patient from giving informed consent&#xD;
&#xD;
          -  Medical conditions such as uncontrolled infection, uncontrolled diabetes mellitus or&#xD;
             connective tissue disease&#xD;
&#xD;
          -  Participants with a &quot;currently active&quot; second malignancy other than non-melanoma skin&#xD;
             cancers&#xD;
&#xD;
          -  Patients with diffuse (&gt; 1 quadrant or &gt;5cm) suspicious microcalcifications&#xD;
&#xD;
          -  Women who are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alphonse Taghian, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 6, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2008</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Alphonse Taghian, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Radiation Oncology, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>non-invasive breast cancer</keyword>
  <keyword>early invasive breast cancer</keyword>
  <keyword>radiation</keyword>
  <keyword>PBI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

